Species specificity of the complement inhibitor compstatin investigated by all‐atom molecular dynamics simulations

The development of compounds to regulate the activation of the complement system in non‐primate species is of profound interest because it can provide models for human diseases. The peptide compstatin inhibits protein C3 in primate mammals and is a potential therapeutic agent against unregulated activation of complement in humans but is inactive against nonprimate species. Here, we elucidate this species specificity of compstatin by molecular dynamics simulations of complexes between the most potent natural compstatin analog and human or rat C3. The results are compared against an experimental conformation of the human complex, determined recently by X‐ray diffraction at 2.4‐Å resolution. The human complex simulations provide information on the relative contributions to stability of specific C3 and compstatin residues. In the rat simulations, the protein undergoes reproducible conformational changes, which eliminate or weaken specific interactions and reduce the complex stability. The simulation insights can be used to design improved compstatin‐based inhibitors for human C3 and active inhibitors against lower mammals. Proteins 2010. © 2010 Wiley‐Liss, Inc.

[1]  Alexander D. MacKerell,et al.  Extending the treatment of backbone energetics in protein force fields: Limitations of gas‐phase quantum mechanics in reproducing protein conformational distributions in molecular dynamics simulations , 2004, J. Comput. Chem..

[2]  John D Lambris,et al.  Compstatin inhibits complement activation by binding to the beta-chain of complement factor 3. , 2006, Molecular immunology.

[3]  M. Karplus,et al.  Simulation of activation free energies in molecular systems , 1996 .

[4]  John D Lambris,et al.  Development of a New Pharmacophore Model That Discriminates Active Compstatin Analogs , 2008, Chemical biology & drug design.

[5]  Dimitrios Morikis,et al.  Binding Kinetics, Structure-Activity Relationship, and Biotransformation of the Complement Inhibitor Compstatin1 , 2000, The Journal of Immunology.

[6]  M. Gilson,et al.  Calculation of protein-ligand binding affinities. , 2007, Annual review of biophysics and biomolecular structure.

[7]  S. Zographos,et al.  Glycogen phosphorylase inhibitors: A free energy perturbation analysis of glucopyranose spirohydantoin analogues , 2005, Proteins.

[8]  Hoover,et al.  Canonical dynamics: Equilibrium phase-space distributions. , 1985, Physical review. A, General physics.

[9]  John D Lambris,et al.  Structural aspects and design of low-molecular-mass complement inhibitors. , 2001, Biochemical Society transactions.

[10]  Christodoulos A Floudas,et al.  Integrated computational and experimental approach for lead optimization and design of compstatin variants with improved activity. , 2003, Journal of the American Chemical Society.

[11]  John D Lambris,et al.  Inhibition of human complement by a C3-binding peptide isolated from a phage-displayed random peptide library. , 1996, Journal of immunology.

[12]  B. Brooks,et al.  Constant pressure molecular dynamics simulation: The Langevin piston method , 1995 .

[13]  T. Simonson,et al.  Free‐Energy Simulations and Experiments Reveal Long‐Range Electrostatic Interactions and Substrate‐Assisted Specificity in an Aminoacyl‐tRNA Synthetase , 2006, Chembiochem : a European journal of chemical biology.

[14]  C. Brooks,et al.  Balancing solvation and intramolecular interactions: toward a consistent generalized Born force field. , 2006, Journal of the American Chemical Society.

[15]  N. Oikonomakos,et al.  Recognition of ribonuclease A by 3'-5'-pyrophosphate-linked dinucleotide inhibitors: a molecular dynamics/continuum electrostatics analysis. , 2007, Biophysical journal.

[16]  T. Darden,et al.  Particle mesh Ewald: An N⋅log(N) method for Ewald sums in large systems , 1993 .

[17]  John D Lambris,et al.  Complement inhibitors: a resurgent concept in anti-inflammatory therapeutics. , 2000, Immunopharmacology.

[18]  John D Lambris,et al.  Structure of Compstatin in Complex with Complement Component C3c Reveals a New Mechanism of Complement Inhibition* , 2007, Journal of Biological Chemistry.

[19]  Dimitrios Morikis,et al.  Studies of Structure-Activity Relations of Complement Inhibitor Compstatin. , 2004, The Journal of Immunology.

[20]  P. Kollman,et al.  Combined molecular mechanical and continuum solvent approach (MM-PBSA/GBSA) to predict ligand binding , 2000 .

[21]  Arieh Warshel,et al.  Absolute binding free energy calculations: On the accuracy of computational scoring of protein–ligand interactions , 2010, Proteins.

[22]  H. K. Fung,et al.  New compstatin variants through two de novo protein design frameworks. , 2010, Biophysical journal.

[23]  John I. Gallin,et al.  Inflammation: Basic Principles and Clinical Correlates , 1992 .

[24]  John D Lambris,et al.  Improvement of the anti-C3 activity of compstatin using rational and combinatorial approaches. , 2004, Biochemical Society transactions.

[25]  Jianpeng Ma,et al.  CHARMM: The biomolecular simulation program , 2009, J. Comput. Chem..

[26]  John L. Klepeis,et al.  Predicting peptide structures using NMR data and deterministic global optimization , 1999, J. Comput. Chem..

[27]  G. Ciccotti,et al.  Numerical Integration of the Cartesian Equations of Motion of a System with Constraints: Molecular Dynamics of n-Alkanes , 1977 .

[28]  Alexander D. MacKerell,et al.  CH/π interactions involving aromatic amino acids: Refinement of the CHARMM tryptophan force field , 2005, J. Comput. Chem..

[29]  Rodrigo Lopez,et al.  Clustal W and Clustal X version 2.0 , 2007, Bioinform..

[30]  J. Lambris,et al.  Structural Biology of the Complement System , 2005 .

[31]  Richard H. Henchman,et al.  Revisiting free energy calculations: a theoretical connection to MM/PBSA and direct calculation of the association free energy. , 2004, Biophysical journal.

[32]  John L. Klepeis,et al.  Design of peptide analogues with improved activity using a novel de novo protein design approach , 2004 .

[33]  Christodoulos A. Floudas,et al.  Structure-Based Integrative Computational and Experimental Approach for the Optimization of Drug Design , 2005, International Conference on Computational Science.

[34]  Alexander D. MacKerell,et al.  All-atom empirical potential for molecular modeling and dynamics studies of proteins. , 1998, The journal of physical chemistry. B.

[35]  Dimitrios Morikis,et al.  Compstatin, a peptide inhibitor of complement, exhibits species-specific binding to complement component C3. , 2003, Molecular immunology.

[36]  K Schulten,et al.  VMD: visual molecular dynamics. , 1996, Journal of molecular graphics.

[37]  L. R. Scott,et al.  Electrostatics and diffusion of molecules in solution: simulations with the University of Houston Brownian dynamics program , 1995 .

[38]  John D Lambris,et al.  Structure‐kinetic relationship analysis of the therapeutic complement inhibitor compstatin , 2009, Journal of molecular recognition : JMR.

[39]  John D Lambris,et al.  Conformational analysis of compstatin analogues with molecular dynamics simulations in explicit water. , 2007, Journal of molecular graphics & modelling.

[40]  Dimitrios Morikis,et al.  The Structural Basis of Compstatin Activity Examined by Structure-Function-based Design of Peptide Analogs and NMR* 210 , 2002, The Journal of Biological Chemistry.

[41]  Piet Gros,et al.  Structures of complement component C3 provide insights into the function and evolution of immunity , 2005, Nature.

[42]  John D Lambris,et al.  Structure, Dynamics, Activity, and Function of Compstatin and Design of More Potent Analogues , 2005 .

[43]  T. Simonson,et al.  Probing electrostatic interactions and ligand binding in aspartyl‐tRNA synthetase through site‐directed mutagenesis and computer simulations , 2007, Proteins.

[44]  S. Nosé.  A unified formulation of the constant temperature molecular dynamics methods , 1984 .

[45]  Dimitrios Morikis,et al.  Solution structure of Compstatin, a potent complement inhibitor , 1998, Protein science : a publication of the Protein Society.

[46]  John D Lambris,et al.  Synthetic small-molecule complement inhibitors. , 2004, Current opinion in investigational drugs.

[47]  W. L. Jorgensen,et al.  Comparison of simple potential functions for simulating liquid water , 1983 .

[48]  Amedeo Caflisch,et al.  Wordom: a program for efficient analysis of molecular dynamics simulations , 2007, Bioinform..

[49]  Dimitrios Morikis,et al.  Design and NMR characterization of active analogues of compstatin containing non-natural amino acids. , 2005, Journal of medicinal chemistry.

[50]  Dimitrios Morikis,et al.  Conformational interconversion in compstatin probed with molecular dynamics simulations , 2003, Proteins.

[51]  Roland L. Dunbrack,et al.  proteins STRUCTURE O FUNCTION O BIOINFORMATICS Improved prediction of protein side-chain conformations with SCWRL4 , 2022 .

[52]  D. Morikis,et al.  Development of a quasi-dynamic pharmacophore model for anti-complement peptide analogues. , 2005, Journal of the American Chemical Society.

[53]  Charles L. Brooks,et al.  Generalized born model with a simple smoothing function , 2003, J. Comput. Chem..

[54]  Conformational analysis of compstatin analogues with molecular dynamics simulations in explicit water. , 2007 .